OpenAI acquires Orchestra Bio to fold drug-development orchestration into Rosalind
OpenAI says it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and is combining the team and technology with Rosalind, its life-sciences models and tools including GPT-Rosalind and Rosalind Workbench.
On Oct 20, 2026, OpenAI announced it has acquired Orchestra Bio—a platform that helps biopharma teams coordinate the complex process of drug development—and is bringing Orchestra’s team and technology together with Rosalind, OpenAI’s AI models and tools for life-sciences research. The post says GPT-Rosalind helps scientists reason through biology and chemistry questions, while Rosalind Workbench connects those capabilities with scientific tools and data; Orchestra contributes a team experienced across biotech, software, and AI plus a platform built to coordinate drug programs.
OpenAI describes Orchestra Bio as a place where people and AI agents advance drug programs together: scientists and program leaders delegate monitoring and tracking of studies and campaigns to agents so they can focus on decisions. A manufacturing-batch failure, for example, can delay a trial start; agents help identify affected activities and timelines, gather information, and compare response options. The company cites a roughly 10-to-15-year average from target discovery to U.S. regulatory approval and situates the deal alongside existing life-sciences collaborations such as Novo Nordisk and Moderna. Deal price and closing terms are not disclosed in the post.
Sources
- OpenAI acquires Orchestra Bio — OpenAI